• AtriCure Inc ATRC.OQ reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of nine analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -14 cents to -9 cents per share.

• Revenue rose 15.8% to $134.27 million from a year ago; analysts expected $131.25 million.

• AtriCure Inc's reported EPS for the quarter was a loss of 1 cent​.

• The company reported a quarterly loss of $267 thousand.

• AtriCure Inc shares had risen by 3.4% this quarter and gained 19.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

• Wall Street's median 12-month price target for AtriCure Inc is $51.50, about 29.2% above its last closing price of $36.45

This summary was machine generated from LSEG data October 29 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)